Definition of a Conserved Immunodominant Domain on Hepatitis C Virus E2 Glycoprotein by Neutralizing Human Monoclonal Antibodies
about
Genetic Diversity Underlying the Envelope Glycoproteins of Hepatitis C Virus: Structural and Functional Consequences and the Implications for Vaccine DesignThe hepatitis C virus glycan shield and evasion of the humoral immune responseNeutralizing antibody response to hepatitis C virusIdentification of a Residue in Hepatitis C Virus E2 Glycoprotein That Determines Scavenger Receptor BI and CD81 Receptor Dependency and Sensitivity to Neutralizing AntibodiesIn vitro selection of a neutralization-resistant hepatitis C virus escape mutantMutations in Hepatitis C Virus E2 Located outside the CD81 Binding Sites Lead to Escape from Broadly Neutralizing Antibodies but Compromise Virus InfectivityLow pH-dependent Hepatitis C Virus Membrane Fusion Depends on E2 Integrity, Target Lipid Composition, and Density of Virus ParticlesHepatitis C Virus (HCV) Infection May Elicit Neutralizing Antibodies Targeting Epitopes Conserved in All Viral GenotypesToward a Hepatitis C Virus Vaccine: the Structural Basis of Hepatitis C Virus Neutralization by AP33, a Broadly Neutralizing AntibodyStructural basis of hepatitis C virus neutralization by broadly neutralizing antibody HCV1CD81 is dispensable for hepatitis C virus cell-to-cell transmission in hepatoma cellsHuman monoclonal antibodies to a novel cluster of conformational epitopes on HCV E2 with resistance to neutralization escape in a genotype 2a isolateNaturally occurring antibodies that recognize linear epitopes in the amino terminus of the hepatitis C virus E2 protein confer noninterfering, additive neutralizationCapitalizing on knowledge of hepatitis C virus neutralizing epitopes for rational vaccine designThe core domain of hepatitis C virus glycoprotein E2 generates potent cross-neutralizing antibodies in guinea pigsAdaptation of hepatitis C virus to mouse CD81 permits infection of mouse cells in the absence of human entry factors.Hepatitis C virus hypervariable region 1 modulates receptor interactions, conceals the CD81 binding site, and protects conserved neutralizing epitopes.Mutations within a conserved region of the hepatitis C virus E2 glycoprotein that influence virus-receptor interactions and sensitivity to neutralizing antibodies.Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection.Selection pressure from neutralizing antibodies drives sequence evolution during acute infection with hepatitis C virus.Intracytoplasmic stable expression of IgG1 antibody targeting NS3 helicase inhibits replication of highly efficient hepatitis C Virus 2a clone.Non-random escape pathways from a broadly neutralizing human monoclonal antibody map to a highly conserved region on the hepatitis C virus E2 glycoprotein encompassing amino acids 412-423Affinity maturation to improve human monoclonal antibody neutralization potency and breadth against hepatitis C virus.Structural basis for broad neutralization of hepatitis C virus quasispecies.Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virusFine mapping of murine antibody responses to immunization with a novel soluble form of hepatitis C virus envelope glycoprotein complex.Adaptive immunity to hepatitis C virus.Mapping a region of hepatitis C virus E2 that is responsible for escape from neutralizing antibodies and a core CD81-binding region that does not tolerate neutralization escape mutations.Breadth of neutralization and synergy of clinically relevant human monoclonal antibodies against HCV genotypes 1a, 1b, 2a, 2b, 2c, and 3a.Molecular and contextual markers of hepatitis C virus and drug abuse.Hepatitis C Virus E1 and E2 Proteins Used as Separate Immunogens Induce Neutralizing Antibodies with Additive PropertiesMonoclonal Antibodies Directed toward the Hepatitis C Virus Glycoprotein E2 Detect Antigenic Differences Modulated by the N-Terminal Hypervariable Region 1 (HVR1), HVR2, and Intergenotypic Variable RegionNeutralizing antibodies and pathogenesis of hepatitis C virus infection.Cooperativity in virus neutralization by human monoclonal antibodies to two adjacent regions located at the amino terminus of hepatitis C virus E2 glycoproteinBroadly neutralizing antibodies present new prospects to counter highly antigenically diverse viruses.Broad Anti-Hepatitis C Virus (HCV) Antibody Responses Are Associated with Improved Clinical Disease Parameters in Chronic HCV InfectionSequence and functional analysis of the envelope glycoproteins of hepatitis C virus variants selectively transmitted to a new host.Global mapping of antibody recognition of the hepatitis C virus E2 glycoprotein: Implications for vaccine design.A neutralization epitope in the hepatitis C virus E2 glycoprotein interacts with host entry factor CD81.CD81 and hepatitis C virus (HCV) infection.
P2860
Q26801759-08FDED89-2CB9-40C4-9CC9-A6AC565402B8Q27023390-4AAC47C5-E49E-470B-A94B-5E8A478B4ABFQ27027484-1F1EA7B9-5AD2-4442-B0BD-02951A3F95EAQ27487399-A73F25EA-DF4F-4B88-8533-2D591025D079Q27487549-E7899BD0-E414-4A33-A799-C892DF4C29D6Q27488430-404D2A64-3E05-45C4-99B0-143129AF57DAQ27489056-098F663C-05DC-41B9-B3FC-A677D8AA8D1FQ27490450-F33F2B85-B10C-482C-9A81-EE5B62ADA7E3Q27673453-5ED3955B-AA5E-41AD-ADAD-6685FBCEC178Q27679280-4FE11F4C-A39F-4F83-9062-B55674EFEE51Q28114859-80FC1E4A-B0E3-4138-8EB0-9C6BA6A23BEFQ28482261-4C0D42A5-EF65-4BF5-82DE-A46E339A0092Q28731355-CCB48E9B-1742-48AF-B977-5EAFBE5D020FQ30374314-804EEA62-210E-454A-BF93-089BE727D9B6Q33612608-62358D53-04B2-417A-AE86-2466B1286413Q33628805-4A6D0C70-4B90-4566-A62C-BBFE924C2C2BQ33877342-DC75A759-A09F-4664-8527-2DB1828B1598Q33877381-456CAE80-EC10-4366-AA3C-C6AB8A66C0B7Q33929089-3871A545-D904-4536-999E-998604A1CEA8Q33955998-279721AD-D0BD-45CF-9576-30D1C42A5243Q33991988-8AD2865B-1883-4204-98DE-D750C47D11EFQ34047477-FDD785D9-1D6B-475A-8EF2-8459582E221FQ34048752-A14469DF-CDBE-44EE-A83B-2572B01E3579Q34064882-8BF5CE3A-3BD3-44E8-B052-A780BAA55A16Q34228030-7ECD5710-3AFE-487F-8E68-C02BE282E9ADQ34262165-F827A241-ED8E-416C-9DA8-6AD1DCC55F60Q35259748-1AB77D9B-A17A-4589-ADB6-938E6FCE41C9Q35274913-91B90E76-89C0-42F9-B838-306BA5FDFEE1Q35557994-8EF0DFDA-9CB6-4EB2-B66F-E288AE7E1A85Q35660841-074AD44E-331C-4106-894A-819F246B3560Q35953659-19A3FAAF-D2D3-45B7-8798-C3987EC92295Q36334312-ABF947DA-102E-4896-9281-DDE4CB2AA65DQ36395837-B18FC2A8-3E16-4B92-AB37-9D5C510E190DQ36506935-63C8F5B1-2548-48D3-B140-78B0E80D05E0Q36693991-C0ABED4A-9C4F-45F4-B2B0-6D0639F980A4Q36811958-D7746ABF-2349-40AD-883B-10DF31211B0CQ37336742-8E476D74-91EC-4816-B758-06AE7C36E391Q37417999-5F6F3919-08C9-492D-9BC5-DD8067B738A6Q37439266-BE358AE1-18A2-4F99-A6B1-321A5AB549B2Q37611819-37A84667-6A0B-40B9-B6D1-FF86FF603104
P2860
Definition of a Conserved Immunodominant Domain on Hepatitis C Virus E2 Glycoprotein by Neutralizing Human Monoclonal Antibodies
description
2008 nî lūn-bûn
@nan
2008 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Definition of a Conserved Immu ...... ng Human Monoclonal Antibodies
@ast
Definition of a Conserved Immu ...... ng Human Monoclonal Antibodies
@en
Definition of a Conserved Immu ...... ng Human Monoclonal Antibodies
@nl
type
label
Definition of a Conserved Immu ...... ng Human Monoclonal Antibodies
@ast
Definition of a Conserved Immu ...... ng Human Monoclonal Antibodies
@en
Definition of a Conserved Immu ...... ng Human Monoclonal Antibodies
@nl
prefLabel
Definition of a Conserved Immu ...... ng Human Monoclonal Antibodies
@ast
Definition of a Conserved Immu ...... ng Human Monoclonal Antibodies
@en
Definition of a Conserved Immu ...... ng Human Monoclonal Antibodies
@nl
P2093
P2860
P356
P1433
P1476
Definition of a Conserved Immu ...... ng Human Monoclonal Antibodies
@en
P2093
Arvind H Patel
Jinming Xia
Meital Gal-Tanamy
Sophia H Li
Stanley M Lemon
Steven K H Foung
Zhen-Yong Keck
P2860
P304
P356
10.1128/JVI.02475-07
P577
2008-06-01T00:00:00Z